![conference banner](/images/conference-banner.jpeg)
Abstract
In the central nervous system (CNS), abnormal deposition of insoluble protein aggregates or inclusion bodies within nerve cells is commonly observed in association with several neurodegenerative diseases. The ubiquitinated protein aggregates are believed to result from malfunction or overload of the ubiquitin-proteasome pathway or from structural changes in the protein substrates which prevent their recognition and degradation by the ubiquitin-proteasome pathway. Impaired proteolysis might also contribute to the synaptic dysfunction seen early in neurodegenerative diseases because the ubiquitin-proteasome pathway is known to play a role in normal functioning of synapses. Because specificity of the ubiquitin proteasome mediated proteolysis is determined by specific ubiquitin ligases (E3s), identification of specific E3s and their allosteric modulators are likely to provide effective therapeutic targets for the treatment of several CNS disorders. Another unexplored area for the discovery of drug targets is the proteasome. Although many inhibitors of the proteasome are available, no effective drugs exist that can stimulate the proteasome. Since abnormal protein aggregation is a common feature of different neurodegenerative diseases, enhancement of proteasome activity might be an efficient way to remove the aggregates that accumulate in the brain. In this review, we discuss how the components of the ubiquitinproteasome pathway could be potential targets for therapy of CNS diseases and disorders.
Keywords: ubiquitin ligase, proteasome activator, proteolysis, neurodegenerative diseases, synaptic dysfunction, protein aggregation, neuron
Current Pharmaceutical Design
Title: Ubiquitin-Proteasome Pathway Components as Therapeutic Targets for CNS Maladies
Volume: 11 Issue: 29
Author(s): S. C. Upadhya and A. N. Hegde
Affiliation:
Keywords: ubiquitin ligase, proteasome activator, proteolysis, neurodegenerative diseases, synaptic dysfunction, protein aggregation, neuron
Abstract: In the central nervous system (CNS), abnormal deposition of insoluble protein aggregates or inclusion bodies within nerve cells is commonly observed in association with several neurodegenerative diseases. The ubiquitinated protein aggregates are believed to result from malfunction or overload of the ubiquitin-proteasome pathway or from structural changes in the protein substrates which prevent their recognition and degradation by the ubiquitin-proteasome pathway. Impaired proteolysis might also contribute to the synaptic dysfunction seen early in neurodegenerative diseases because the ubiquitin-proteasome pathway is known to play a role in normal functioning of synapses. Because specificity of the ubiquitin proteasome mediated proteolysis is determined by specific ubiquitin ligases (E3s), identification of specific E3s and their allosteric modulators are likely to provide effective therapeutic targets for the treatment of several CNS disorders. Another unexplored area for the discovery of drug targets is the proteasome. Although many inhibitors of the proteasome are available, no effective drugs exist that can stimulate the proteasome. Since abnormal protein aggregation is a common feature of different neurodegenerative diseases, enhancement of proteasome activity might be an efficient way to remove the aggregates that accumulate in the brain. In this review, we discuss how the components of the ubiquitinproteasome pathway could be potential targets for therapy of CNS diseases and disorders.
Export Options
About this article
Cite this article as:
Upadhya C. S. and Hegde N. A., Ubiquitin-Proteasome Pathway Components as Therapeutic Targets for CNS Maladies, Current Pharmaceutical Design 2005; 11 (29) . https://dx.doi.org/10.2174/138161205774580651
DOI https://dx.doi.org/10.2174/138161205774580651 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Traditional Uses, Pharmacological, and Phytochemical Studies of
<i>Euphorbia</i>: A Review
Current Topics in Medicinal Chemistry Novel Vaginal Drug Delivery Systems: A Review
Current Drug Therapy Discovery of Hedgehog Antagonists for Cancer Therapy
Current Medicinal Chemistry Inflammation and Thrombophilia in Pregnancy Complications: Implications for Risk Assessment and Clinical Management
Cardiovascular & Hematological Disorders-Drug Targets A Novel Series of N-aryltriazole and N-acridinyltriazole Hybrids as Potential Anticancer Agents
Current Organic Synthesis Genetic Surgery - A Right Strategy to Attack Cancer
Current Gene Therapy Research Progress in Flavonoids as Potential Anticancer Drug Including Synergy with Other Approaches
Current Topics in Medicinal Chemistry The Type II Transmembrane Serine Protease, Matriptase-2: Possible Links to Cancer?
Anti-Cancer Agents in Medicinal Chemistry Removing Protein Aggregates: The Role of Proteolysis in Neurodegeneration
Current Medicinal Chemistry Immune Checkpoint Regulators: A New Era Toward Promising Cancer Therapy
Current Cancer Drug Targets Human Pluripotent Stem Cells for Spinal Cord Injury
Current Stem Cell Research & Therapy Novel PARP Inhibitor DDPF-20 Induces DNA Damage and Inhibits Angiogenesis through the PI3K/Akt/VEGF Pathway
Anti-Cancer Agents in Medicinal Chemistry Targeting Post-Ejaculation Sperm for Value-Added Contraception
Current Molecular Pharmacology Cerebral Artery Signal Transduction Mechanisms: Developmental Changes in Dynamics and Ca<sup>2+</sup> Sensitivity
Current Vascular Pharmacology Pulmonary Squamous Papilloma Complicating Recurrent Tracheal Papillomatosis
Current Respiratory Medicine Reviews Multifunctional Proteins in Tumorigenesis: Aminoacyl-tRNA Synthetases and Translational Components
Current Proteomics Prevention of Cancer in the Upper Gastrointestinal Tract with COX-Inhibition. Still an Option?
Current Pharmaceutical Design The Dynamics of the Hypothalamic-Pituitary-Ovarian Axis, ReproductivePerformance and Sexuality Following Bariatric Surgery
Current Women`s Health Reviews Medicinal Importance, Pharmacological Activities, and Analytical Aspects of Engeletin in Medicine: Therapeutic Benefit Through Scientific Data Analysis
Endocrine, Metabolic & Immune Disorders - Drug Targets The Functions of Polo-Like Kinases and their Relevance to Human Disease
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents